Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.

CANF

Can Fite BioPharma (CANF)

Can Fite BioPharma Ltd
Date:
Sort by:
 Showing the most relevant articles for your search:AMEX:CANF
DateTimeSourceHeadlineSymbolCompany
25/04/202421:00Business WireLong-term Complete Response to Can-Fite's Namodenoson in Patient with Advanced Liver Cancer: Article Published in a Leading Scientific JournalAMEX:CANFCan Fite BioPharma Ltd
15/04/202421:00Business WireCan-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASHAMEX:CANFCan Fite BioPharma Ltd
03/04/202422:00Business WireCan-Fite: Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH PatientsAMEX:CANFCan Fite BioPharma Ltd
28/03/202422:00Business WireCan-Fite Reports 2023 Financial Results and Clinical UpdateAMEX:CANFCan Fite BioPharma Ltd
11/03/202422:27Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]AMEX:CANFCan Fite BioPharma Ltd
11/03/202422:00Business WireNamodenoson Treatment for Pancreatic and Liver Cancer: Data will be Discussed in Out-licensing and Distribution Partnering Meetings at Bio Europe ConferenceAMEX:CANFCan Fite BioPharma Ltd
28/02/202423:06Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]AMEX:CANFCan Fite BioPharma Ltd
28/02/202423:00Business WireCan-Fite Broadens its Strong Intellectual Property (IP) for NASH: Received Patent Allowance in CanadaAMEX:CANFCan Fite BioPharma Ltd
15/02/202407:32Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsAMEX:CANFCan Fite BioPharma Ltd
30/01/202423:24Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]AMEX:CANFCan Fite BioPharma Ltd
30/01/202423:00Business WireCan-Fite Expands the Out-Licensing Deal with Ewopharma to Include the Pancreatic Cancer IndicationAMEX:CANFCan Fite BioPharma Ltd
29/01/202423:05Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]AMEX:CANFCan Fite BioPharma Ltd
29/01/202423:00Business WireCan-Fite: Top Scientific Journal Published Positive Data from the COMFORT-1 Phase III Psoriasis StudyAMEX:CANFCan Fite BioPharma Ltd
08/01/202416:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessAMEX:CANFCan Fite BioPharma Ltd
29/12/202308:16Edgar (US Regulatory)Form F-3/A - Registration statement by foreign private issuers: [Amend]AMEX:CANFCan Fite BioPharma Ltd
20/12/202323:09Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]AMEX:CANFCan Fite BioPharma Ltd
20/12/202323:00Business WireThe Anti-Obesity Effect of Can-Fite’s Namodenoson: Molecular Mechanism of Action in Pre-clinical and Human StudiesAMEX:CANFCan Fite BioPharma Ltd
18/12/202323:07Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]AMEX:CANFCan Fite BioPharma Ltd
18/12/202323:00Business WireCan-Fite Received FDA Positive Response to Psoriasis Pediatric PlanAMEX:CANFCan Fite BioPharma Ltd
13/12/202308:15Edgar (US Regulatory)Form F-3 - Registration statement by foreign private issuersAMEX:CANFCan Fite BioPharma Ltd
04/12/202323:05Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]AMEX:CANFCan Fite BioPharma Ltd
04/12/202323:00Business WireCan-Fite’s Namodenoson for the Treatment of Pancreatic Cancer Patients: Progress in Clinical DevelopmentAMEX:CANFCan Fite BioPharma Ltd
30/11/202323:05Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]AMEX:CANFCan Fite BioPharma Ltd
30/11/202323:00Business WireCan-Fite Reports Third Quarter 2023 Financial Results and Clinical UpdateAMEX:CANFCan Fite BioPharma Ltd
23/11/202308:20Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]AMEX:CANFCan Fite BioPharma Ltd
23/11/202308:15Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]AMEX:CANFCan Fite BioPharma Ltd
22/11/202308:30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]AMEX:CANFCan Fite BioPharma Ltd
22/11/202305:53GlobeNewswire Inc.Can-Fite Announces Exercise of Warrants for Approximately $3.0 Million in Gross ProceedsAMEX:CANFCan Fite BioPharma Ltd
21/11/202323:03Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]AMEX:CANFCan Fite BioPharma Ltd
21/11/202323:00Business WireCan-Fite: Complete Response and 6.9 Years Overall Survival in a Patient with Advanced Liver Cancer Treated with NamodenosonAMEX:CANFCan Fite BioPharma Ltd
 Showing the most relevant articles for your search:AMEX:CANF